← All drugs Report issue

Acorafloxacin

Small moleculeexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

0

Phase 2

2

Phase 3

0

Phase 4

0

Earliest trial started Jun 1, 2010 (NCT01128530)

Timeline

2010s

Jan 1, 2010
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Gyrase BINHIBITOR
Q6S6F1 inhibitor
- B subunit of DNA gyrase (Q6S6F1) ↗
Topoisomerase IVINHIBITOR
Topoisomerase IV inhibitor
- DNA topoisomerase 4 subunit A (parC) ↗
- DNA topoisomerase 4 subunit B (parE) ↗
- Topoisomerase IV subunit A
- DNA topoisomerase 4 subunit B
Bacterial DNA gyraseINHIBITOR
Bacterial DNA gyrase inhibitor
- DNA gyrase subunit B (GYRB) ↗
- DNA gyrase subunit A (gyrA) ↗
- DNA gyrase subunit B
- DNA gyrase subunit A

Chemistry & pharmacology

Loading structure…

SMILES

COc1c(N2CCC/C(=C(\F)CN)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12

Mol. weight: 419.43 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL1257096 ↗

Also known as

jnj-32729463

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01198626	Phase 2	Oct 1, 2010	Furiex
NCT01128530	Phase 2	Jun 1, 2010	Furiex

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Furiex	For profit	2	2	1	2010

1 organizations

Page 1 / 1